Who makes AD-115A, AD-1151?

AD-115A, AD-1151 is developed by Addpharma Inc..

What development phase is AD-115A, AD-1151 in?

AD-115A, AD-1151 is in Phase 1.

Last reviewed 2026-04-23 · How we verify

AD-115A, AD-1151

Addpharma Inc. · Phase 1 active Small molecule

At a glance

Generic name	AD-115A, AD-1151
Sponsor	Addpharma Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151' (PHASE1)
The Study Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151' (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AD-115A, AD-1151 CI brief — competitive landscape report
AD-115A, AD-1151 updates RSS · CI watch RSS
Addpharma Inc. portfolio CI